![\"\"\/](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/11\/Shutterstock_2419837881-430x241.jpg\")
<\/p>\n <\/p>\n
Biocat\u2019s Monserrat Dabban urged stakeholders in European biopharma to see innovation through AI-driven data analytics as the route to future competitive success. Credit: Ivan Marc \/ Shutterstock.com.<\/p>\n
Europe\u2019s biopharma stakeholders should seek innovation through AI to meet the challenges of treatment resistance, drug affordability, and a creeping patent cliff, channelling the continent\u2019s health data to catch up to more competitive industries in the US and China.<\/p>\n
This was the view Montserrat Dabban outlined in her keynote address at the 2025 CPHI conference, which took place on 28\u201330 October in Frankfurt. Dabban is the director of strategic foresight and international relations at Biocat, a public-private entity to support the healthcare ecosystem in Catalonia, Spain. <\/p>\n
![\"\"\/](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/GMS-logo.svg\"){kind=logo}
Discover B2B Marketing That Performs <\/p>\n
\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n
She said that stakeholders in the European biopharma industry could find innovative solutions to challenges in several key areas by using AI to leverage the vast amounts of data collected by health systems for drug discovery<\/a> and improved trial design<\/a>.<\/p>\n Dabban identified several key challenges faced by the global biopharma industry today, including logistical ones like scaling up cell and gene therapies<\/a>, improving clinical trial speeds, drug affordability, as well as the uncertainties of supply chain resilience<\/a>, sustainability, and pandemic preparedness.<\/p>\n Meanwhile, she noted the industry faces an oncoming wave of drug patent expiries<\/a>, risking billions of dollars in total annual revenues: \u201cPipelines are thinning \u2026 pipeline growth slowed.\u201d <\/p>\n Additionally, current research trends have a lopsided focus on development in metabolic, immunological, and oncological diseases at the expense of other indications.<\/p>\n To avoid the pitfalls of what Dabban termed \u201ctherapeutic saturation\u201d \u2014 too many molecules developed for too few targets \u2014 she said all stakeholders in European biopharma must cooperate in addressing several key domains: aging populations, brain health, cancer, antimicrobial resistance, health equity, and rare disease. To do so, she pointed to upscaling the utilisation of Europe\u2019s extensive health databases<\/a>.<\/p>\n Dabban said that improved use of data from wearable devices<\/a> can open the door to digital phenotyping, improved biomarkers, and centralised endpoints in neurological trials. For example, in oncology, she suggested exploring adaptive trials and federated analytics so that data from multiple sources can be analysed without needing to be centralised.<\/p>\n But Dabban told attendees that a vast data store was \u201cuseless if it\u2019s not processed, and we need technology for that\u201d. Hence, AI would prove key to effectively processing health data as a means to developing faster clinical trials with more focussed endpoints, she said. <\/p>\n \u201cWe are at a crossroads. We have to seize the moment for Europe \u2026 we have to expect more competition, but also more breakthroughs,\u201d Dabban concluded.<\/p>\n \n Sign up for our daily news round-up! Pharmaceutical Technology Excellence Awards – The Benefits of Entering<\/p>\n Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards<\/strong><\/a> celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don\u2019t miss your chance to stand out\u2014submit your entry today!<\/p>\n
\n\t\t\t\t\t\t\tFind out more <\/a><\/p>\n![\"Email](\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\")
<\/p>\n
\n Give your business an edge with our leading industry insights.\n <\/p>\n